Drug intelligence / Profile preview

imidacloprid

Development stage
Unknown
Lead developer
Bayer CropScience
Modality
Small Molecules
Administration
Topical
01

Overview

Imidacloprid is a systemic insecticide belonging to the neonicotinoid class, which are neuro-active chemicals modeled after nicotine. It acts by binding to and blocking nicotinic acetylcholine receptors in the central nervous system of insects, leading to paralysis and death. Imidacloprid is much more selective for insect receptors than mammalian ones, making it highly toxic to insects but less so to mammals. It is used globally for pest control in agriculture (as a seed treatment or foliar spray), termite control, flea control on pets, and other applications. Originally developed and patented by Bayer CropScience (part of Bayer AG), it has been marketed under numerous trade names and remains widely used despite regulatory restrictions in some regions due to environmental concerns[3][4][5][6].

Brand names
KohinorAdmireAdvantageGauchoMeritConfidorHachikusanPremiseProthorWinner
Other names
imidacloprid
02

Targets

Nicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on imidacloprid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on imidacloprid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call